237 related articles for article (PubMed ID: 23340856)
21. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
22. Polycystic kidney disease: etiology, pathogenesis, and treatment.
Martinez JR; Grantham JJ
Dis Mon; 1995 Nov; 41(11):693-765. PubMed ID: 7587886
[TBL] [Abstract][Full Text] [Related]
23. Mineral bone disease in autosomal dominant polycystic kidney disease.
Gitomer B; Pereira R; Salusky IB; Stoneback JW; Isakova T; Cai X; Dalrymple LS; Ofsthun N; You Z; Malluche HH; Maddux F; George D; Torres V; Chapman A; Steinman TI; Wolf M; Chonchol M
Kidney Int; 2021 Apr; 99(4):977-985. PubMed ID: 32926884
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease.
Mikolajczyk AE; Te HS; Chapman AB
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):17-24. PubMed ID: 27374006
[TBL] [Abstract][Full Text] [Related]
25. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.
Belibi FA; Reif G; Wallace DP; Yamaguchi T; Olsen L; Li H; Helmkamp GM; Grantham JJ
Kidney Int; 2004 Sep; 66(3):964-73. PubMed ID: 15327388
[TBL] [Abstract][Full Text] [Related]
26. The role of DNA damage as a therapeutic target in autosomal dominant polycystic kidney disease.
Zhang JQJ; Saravanabavan S; Munt A; Wong ATY; Harris DC; Harris PC; Wang Y; Rangan GK
Expert Rev Mol Med; 2019 Nov; 21():e6. PubMed ID: 31767049
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD).
Lanoix J; D'Agati V; Szabolcs M; Trudel M
Oncogene; 1996 Sep; 13(6):1153-60. PubMed ID: 8808689
[TBL] [Abstract][Full Text] [Related]
29. Role of keratinocyte growth factor in the pathogenesis of autosomal dominant polycystic kidney disease.
Mei C; Mao Z; Shen X; Wang W; Dai B; Tang B; Wu Y; Cao Y; Zhang S; Zhao H; Sun T
Nephrol Dial Transplant; 2005 Nov; 20(11):2368-75. PubMed ID: 16141466
[TBL] [Abstract][Full Text] [Related]
30. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
31. The FGF23 and Klotho system beyond mineral metabolism.
Kuro-O M
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):64-69. PubMed ID: 27838783
[TBL] [Abstract][Full Text] [Related]
32. Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease.
Rahbari-Oskoui FF
Adv Kidney Dis Health; 2023 Sep; 30(5):417-428. PubMed ID: 38097332
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-β inhibits cystogenesis in human autosomal dominant polycystic kidney epithelial cells.
Elberg D; Jayaraman S; Turman MA; Elberg G
Exp Cell Res; 2012 Aug; 318(13):1508-16. PubMed ID: 22504005
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells.
Silva LM; Jacobs DT; Allard BA; Fields TA; Sharma M; Wallace DP; Tran PV
Sci Rep; 2018 Mar; 8(1):4985. PubMed ID: 29563577
[TBL] [Abstract][Full Text] [Related]
35. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.
Razzaque MS
Nat Rev Endocrinol; 2009 Nov; 5(11):611-9. PubMed ID: 19844248
[TBL] [Abstract][Full Text] [Related]
36. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
38. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.
Donate-Correa J; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
Cytokine Growth Factor Rev; 2012; 23(1-2):37-46. PubMed ID: 22360923
[TBL] [Abstract][Full Text] [Related]
39. Abdominal sonographic study of autosomal dominant polycystic kidney disease.
Nicolau C; Torra R; Bianchi L; Vilana R; Gilabert R; Darnell A; Brú C
J Clin Ultrasound; 2000; 28(6):277-82. PubMed ID: 10867665
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.
Ecder T; Schrier RW
Nat Rev Nephrol; 2009 Apr; 5(4):221-8. PubMed ID: 19322187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
